Altemia (docosahexaenoic acid) / Micelle BioPharma  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Altemia (docosahexaenoic acid) / Micelle BioPharma
SCOT, NCT02604368: A Sickle CEll Disease ComplicatioN Trial

Unknown status
3
210
NA
SC411, Docosahexaenoic acid (DHA), Placebo, Soybean Oil
Micelle BioPharma Inc
Sickle Cell Disease
12/20
12/20
2019-004132-37: A clinical study to determine if a potential new drug (SCD411) is similar to the marketed product Eylea® in the efficacy, is safe and similar tolerable and distributed, by testing its effect on the body in patients with Neovascular Age-related Macular Degeneration

Not yet recruiting
3
576
Europe, RoW
SCD411, Eylea, SCD411, Solution for injection, Eylea
SamChunDang Pharm. Co. Ltd., Sam Chun Dang Pharm. Co. Ltd, SamChunDang Pharm. Co. Ltd.
Neovascular Age-related Macular Degeneration, Age-related macular degeneration (AMD) is a disease that impacts the central area of the retina in the eye, called the macula. AMD is a leading cause of blindness, Diseases [C] - Eye Diseases [C11]
 
 
NCT04480463: A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)

Completed
3
576
Europe, Japan, US, RoW
SCD411, Aflibercept, Eylea®
Sam Chun Dang Pharm. Co. Ltd.
Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
09/22
09/22

Download Options